Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.10 +0.04 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$2.09 -0.01 (-0.43%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CMPX vs. ETNB, AUPH, GYRE, MLYS, WVE, PAHC, ARDX, COLL, NTLA, and RCUS

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Gyre Therapeutics (GYRE), Mineralys Therapeutics (MLYS), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs.

Compass Therapeutics (NASDAQ:CMPX) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends.

Compass Therapeutics' return on equity of -32.37% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -32.37% -30.67%
89bio N/A -59.58%-52.21%

In the previous week, 89bio had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 5 mentions for 89bio and 2 mentions for Compass Therapeutics. 89bio's average media sentiment score of 1.74 beat Compass Therapeutics' score of 1.45 indicating that 89bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
89bio
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Compass Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Compass Therapeutics has higher revenue and earnings than 89bio. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K341.64-$42.49M-$0.41-5.12
89bioN/AN/A-$142.19M-$3.38-2.86

Compass Therapeutics currently has a consensus target price of $13.13, indicating a potential upside of 525.00%. 89bio has a consensus target price of $26.43, indicating a potential upside of 173.87%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Compass Therapeutics is more favorable than 89bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
89bio
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

89bio received 67 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.36% of users gave Compass Therapeutics an outperform vote while only 62.50% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
Compass TherapeuticsOutperform Votes
48
81.36%
Underperform Votes
11
18.64%
89bioOutperform Votes
115
62.50%
Underperform Votes
69
37.50%

68.4% of Compass Therapeutics shares are held by institutional investors. 29.8% of Compass Therapeutics shares are held by insiders. Comparatively, 2.6% of 89bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Compass Therapeutics beats 89bio on 12 of the 17 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$290.39M$2.93B$5.33B$8.39B
Dividend YieldN/A1.68%5.21%4.11%
P/E Ratio-5.6831.1826.7119.71
Price / Sales341.64398.76386.13120.55
Price / CashN/A168.6838.2534.62
Price / Book1.793.236.774.50
Net Income-$42.49M-$72.35M$3.23B$248.22M
7 Day Performance3.96%5.01%1.80%0.56%
1 Month Performance6.06%5.63%11.10%13.17%
1 Year Performance34.62%-27.04%17.11%7.30%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
3.8902 of 5 stars
$2.10
+1.9%
$13.13
+525.0%
+28.8%$290.39M$850,000.00-5.6820Positive News
ETNB
89bio
2.7338 of 5 stars
$7.70
-1.0%
$26.43
+243.2%
+7.4%$1.12BN/A-2.6540Positive News
AUPH
Aurinia Pharmaceuticals
2.4198 of 5 stars
$8.07
-1.5%
$11.50
+42.5%
+49.2%$1.09B$247.30M-53.80300
GYRE
Gyre Therapeutics
0.3745 of 5 stars
$11.11
-2.1%
N/A-20.8%$1.04B$100.64M555.5040News Coverage
MLYS
Mineralys Therapeutics
2.884 of 5 stars
$15.32
-0.2%
$38.00
+148.0%
+29.0%$998.48MN/A-4.2128Analyst Upgrade
WVE
Wave Life Sciences
4.3806 of 5 stars
$6.46
+2.1%
$21.17
+227.7%
-4.4%$995.71M$104.94M-5.82240Positive News
PAHC
Phibro Animal Health
3.5275 of 5 stars
$24.13
+0.5%
$20.00
-17.1%
+26.6%$978.09M$1.19B50.271,860Positive News
ARDX
Ardelyx
4.4944 of 5 stars
$4.06
+4.6%
$10.39
+155.9%
-48.3%$971.38M$361.71M-25.3890Insider Trade
COLL
Collegium Pharmaceutical
4.0425 of 5 stars
$29.83
-1.3%
$43.80
+46.8%
-14.6%$958.50M$664.28M12.86210Positive News
NTLA
Intellia Therapeutics
4.6413 of 5 stars
$9.06
+6.6%
$36.90
+307.3%
-64.2%$938.46M$45.57M-1.67600Positive News
Analyst Forecast
High Trading Volume
RCUS
Arcus Biosciences
3.6663 of 5 stars
$8.70
+1.6%
$25.67
+195.0%
-49.9%$921.20M$141M-2.76500Positive News

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners